🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#ASH22 LBA personally proud to see BMT CTN showing superior GRFS with PTCY in RIC #allo. Practice changing. No negative impact on OS, PFS, relapse. When surviving important to service without #gvhd OncLive.com Shernan Holtan MD Javier Bolaños Meade, MD

Favorable 3 year outcomes in mismatched unrelated donor HCT using PTCy based GVHD prophy. No difference in outcomes observed between 7/8 and <7/8 matched donors. CIBMTR @nmdp Open access link - authors.elsevier.com/c/1gRmb9UKg~Zv…

Great testament to the efforts of our transplant and cell therapy ecosystem and that of our staff who make the CIBMTR a great data resource for our community! @BeTheMatch ASTCT

The CIBMTR #GVHD Working Committee is conducting critical studies into treatment strategies to prevent and treat GVHD. Let’s work together to improve outcomes post-transplant. Join us! #gvhdday @BeTheMatch ASTCT

🎧 Tune in to the must-hear 100th episode of The Onco'Zine - Network Brief with our very own Steve Spellman. Find out how mismatched unrelated donors (#MMUD) hold the key to erasing the gap in donor availability for #HCT 👉 ms.spr.ly/60195u00t

💯

Be the Match Day of Action: Support blood cancer and blood disease patients today! @BTMPublicPolicy votervoice.net/Shares/BwNB2Am…

Ready to discover the latest research on #MRD and precision medicine for #AML patients post-allogeneic #HCT? Join Chief Scientific Director Jeff Auletta for a roundtable discussion with our expert panel to learn more & earn CME credits. 📅 March 9 👉 bit.ly/3IXOYbo

Great panel of speakers discussing Pre-MEASURE findings, presenting case reports, and reviewing MEASURE study PI Chris Hourigan

Listen up! 🎧 The latest episode of the Explore Cell Therapy podcast is now available. Hear more from Steve Spellman and Jeff Auletta about efforts to close equity gaps to ensure a donor is available for all patients who need allogeneic #HCT. Catch up now 👉 bit.ly/3YaW00T

MCC Director Douglas Yee says that biomarker analysis has changed the way we treat breast cancer. It's crucial that more Minnesotans can access this type of testing! Join us in telling the #mnleg to pass SF1948 so more Minnesotans can access #precisionmedicine.

News: Blood test identifies acute myeloid leukemia patients at greater risk for relapse after bone marrow transplant dlvr.it/SkWFwD

Exciting news! The NMDP/#BeTheMatch, CIBMTR & NIH NHLBI have published findings from the Pre-MEASURE study in JAMA. 🔬 This research gives insights on #MRD as a tool to inform #HCT decisions for patients with #AML to improve outcomes. Read more: bit.ly/3YryaxJ

Great opportunity for young investigators to join a working committee CIBMTR Steve Spellman Parinda Mehta Application closing soon! cibmtr.org/CIBMTR/Utility…

The commentary on the study led by Loren Gragert, Steve Spellman, Bronwen Shaw, and Martin Maiers can be found here: doi.org/10.1016/j.jtct…. ASTCT @BeTheMatch Tulane University Medical College of Wisconsin

💯

Brilliant presentation by Dr. B. Shaw from CIBMTR about the era of PTCy #transplantation from unrelated donors. Our long time conceptions about #HLA match significance may need to be updated. Joint The EBMT WMDA session at #EBMT2023. #lifeinHLA #immunogenetics

The largest ever long-term study of people who donated peripheral blood stem cells (#PBSC) show that medicines for these donations are safe. Learn more about this recent CIBMTR study: cibmtr.org/Files/Patient-…

this guy vs. vance. r u kidding me. JD better scurry back to Yale

Our new BMT CTN 1703 analysis busts a few myths: - QOL improved with ptCY - 🩸Cystitis not worse - 2yr GRFS superior 42% vs 29%, p=0.001 - ptCY relapse NOT higher Shernan Holtan MD Javier Bolaños Meade, MD TY to Mike Martens for elegant analysis #GvHD #alloHCT #BMT ascopubs.org/doi/10.1200/JC…